肺炎支原体(MP)已逐渐成为小儿呼吸系统特别是社区获得性肺炎的主要病原,并可引起流行。国内资料统计肺炎支原体肺炎占儿童肺炎住院病人的10%～20%,流行年可达30%,社区获得性肺炎的20%～40%,且有逐年上升的趋势。由于肺炎支原体没有细胞壁,也不能合成胞壁的前体,对干扰细胞壁的抗生素如青霉素、头孢类具有本质耐药性,临床治疗主要选择抑制或影响蛋白质和核 Mycoplasma pneumoniae (MP) has gradually become the major causative agent of pediatric respiratory system, especially community-acquired pneumonia, and can cause epidemics. Domestic data statistics Mycoplasma pneumoniae pneumonia accounted for 10% to 20% of children hospitalized with pneumonia, the popular year up to 30%, community-acquired pneumonia 20% to 40%, and there is a trend of rising year by year. Because Mycoplasma pneumoniae cell wall, cell wall can not be synthesized precursors to interfere with the cell wall antibiotics such as penicillin, cephalosporins with essential resistance, the main choice of clinical treatment inhibit or affect the protein and nucleus